Zai Lab Limited (ZLAB)

Market Cap	4.01B
Revenue (ttm)	398.99M
Net Income (ttm)	-257.10M
Shares Out	107.58M
EPS (ttm)	-2.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,516,799
Open	39.40
Previous Close	36.18
Day's Range	36.60 - 39.78
52-Week Range	13.48 - 39.77
Beta	1.08
Analysts	Buy
Price Target	47.37 (+27.03%)
Earnings Date	May 7, 2025

About ZLAB

Zai Lab Limited develops and commercializes products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; VYVGART, a human IgG1 antibody fragment for myesthenia gravis; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; Qinlock to treat gastr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 1,869
• Stock Exchange: NASDAQ
• Ticker Symbol: ZLAB
• Website: https://www.zailaboratory.com

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for ZLAB stock is "Buy." The 12-month stock price forecast is $47.37, which is an increase of 27.03% from the latest price.

Price Target

$47.37

(27.03% upside)

Analyst Consensus: Buy